LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Начало・Списък с акции・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Затворен

СекторЗдравеопазване

2.21 2.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.09

Максимум

2.26

Ключови измерители
By Trading Economics
Приходи	2.6M -39M
Служители	150
EBITDA	-1.4M -39M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+305.12% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-13M 548M
Предишно отваряне	-0.58
Предишно затваряне	2.21

Настроения в новините

By Acuity

25%

75%

39 / 350 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.18 / 1.69 Подкрепа & съпротива

Allogene Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.03.2026 г., 18:34 ч. UTC

Печалби

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19.03.2026 г., 17:43 ч. UTC

Значими двигатели на пазара

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19.03.2026 г., 23:47 ч. UTC

Печалби

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19.03.2026 г., 23:47 ч. UTC

Печалби

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19.03.2026 г., 23:47 ч. UTC

Печалби

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19.03.2026 г., 23:47 ч. UTC

Печалби

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19.03.2026 г., 23:39 ч. UTC

Печалби

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19.03.2026 г., 23:39 ч. UTC

Печалби

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19.03.2026 г., 23:39 ч. UTC

Печалби

Li Ning: Outdoor Category Continued Growing >2331.HK

19.03.2026 г., 23:38 ч. UTC

Печалби

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19.03.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19.03.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

McCormick Has a Market Value of Around $14.8B -- WSJ

19.03.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19.03.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19.03.2026 г., 22:23 ч. UTC

Пазарно говорене

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19.03.2026 г., 22:09 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19.03.2026 г., 22:06 ч. UTC

Пазарно говорене

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19.03.2026 г., 22:04 ч. UTC

Печалби

Придобивния, сливания и поглъщания

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Значими събития в новините

Global Energy Roundup: Market Talk

19.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Значими събития в новините

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19.03.2026 г., 21:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19.03.2026 г., 20:57 ч. UTC

Значими събития в новините

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

19.03.2026 г., 20:19 ч. UTC

Значими събития в новините

Brent Crude Retreats After Touching $119 -- WSJ

19.03.2026 г., 19:49 ч. UTC

Пазарно говорене

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19.03.2026 г., 19:26 ч. UTC

Значими събития в новините

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19.03.2026 г., 19:10 ч. UTC

Пазарно говорене

Значими събития в новините

Natural Gas Rises in Volatile Trading -- Market Talk

19.03.2026 г., 19:06 ч. UTC

Значими събития в новините

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19.03.2026 г., 18:08 ч. UTC

Пазарно говорене

Значими събития в новините

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Allogene Therapeutics Inc Прогноза

Ценова цел

By TipRanks

305.12% нагоре

12-месечна прогноза

Среден 8.71 USD 305.12%

Висок 14 USD

Нисък 5 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Allogene Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Allogene Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.18 / 1.69Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

39 / 350 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.